RESUMEN
Clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. We present a patient with a diagnosis of schizoaffective disorder who was stable on clozapine for a decade until discontinuation due to thrombocytopenia. She experienced a relapse of her illness, presenting with psychotic and catatonic features with poor oral intake and physical health complications requiring a lengthy admission to the hospital. There was a poor response to alternative antipsychotics and a full course of electroconvulsive therapy. Intramuscular (IM) clozapine was initiated due to catatonia and refusal to accept oral medications. After receiving 10 doses of IM clozapine, she started accepting oral clozapine and made a full recovery within a few weeks. The low platelet count was persistent, and a bone marrow biopsy showed results consistent with immune thrombocytopenia being the cause of that low platelet count.
Asunto(s)
Antipsicóticos , Catatonia , Clozapina , Trombocitopenia , Humanos , Clozapina/efectos adversos , Clozapina/administración & dosificación , Clozapina/uso terapéutico , Trombocitopenia/inducido químicamente , Trombocitopenia/tratamiento farmacológico , Femenino , Catatonia/tratamiento farmacológico , Inyecciones Intramusculares , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Antipsicóticos/uso terapéutico , Trastornos Psicóticos/tratamiento farmacológico , Resultado del Tratamiento , Persona de Mediana EdadAsunto(s)
Catatonia , Hipotiroidismo , Tiroxina , Humanos , Catatonia/tratamiento farmacológico , Catatonia/diagnóstico , Hipotiroidismo/tratamiento farmacológico , Hipotiroidismo/complicaciones , Hipotiroidismo/diagnóstico , Tiroxina/uso terapéutico , Diagnóstico Diferencial , Femenino , Cumplimiento de la Medicación , Persona de Mediana EdadRESUMEN
BACKGROUND: Electroconvulsive therapy (ECT) is highly efficacious in catatonia yet remains underutilized in pediatric patients. Practice guidelines recommend bilateral placement in cases with urgent need for response such as catatonia. Because of significantly lower cognitive burden and efficacy (compared to bilateral), right unilateral placement (RUL) is preferred for major depression. Increasing literature shows RUL is effective for catatonia in adults, but its use in catatonic youth is largely unknown. OBJECTIVES: The aims of the study are to describe naturalistic outcomes of ECT in pediatric patients with catatonia and to discuss ECT parameter considerations. METHODS: This is a retrospective chart review of patients under 18-years of age at Saint Louis Children's Hospital with diagnosis of catatonia who received ECT from 2019 to November 2023. All cases received ECT per clinical protocol. Catatonic symptoms were monitored using the Busch Francis Catatonia Scale. Institutional review board approved the study. RESULTS: Twelve inpatients with debilitating catatonia and a failed benzodiazepine trial underwent ECT. Ten of these 12 patients initiated RUL placement, one received bifrontal, and another bilateral. All patients achieved resolution of catatonia: 6 patients with RUL alone and 4 who started with RUL later switched to bilateral due to nonresponse. The patient receiving bifrontal switched to bilateral due to nonresponse. Patients with malignant catatonia preferentially responded to bilateral placement. Patients experienced expected side effects from ECT. CONCLUSIONS: RUL ECT was effective for catatonia in pediatric patients and can be considered as initial placement. A switch to bilateral can be considered in nonresponse, similar to current approach for major depression. For malignant catatonia, bilateral placement remains preferential.
Asunto(s)
Catatonia , Terapia Electroconvulsiva , Humanos , Catatonia/terapia , Catatonia/complicaciones , Terapia Electroconvulsiva/métodos , Adolescente , Masculino , Femenino , Estudios Retrospectivos , Niño , Resultado del TratamientoRESUMEN
Catatonia is a neuropsychiatric disorder characterized by motor, affective and cognitive-behavioural signs, which lasts from hours to days. Intensive research over the past two decades has led to catatonia being recognized as an independent diagnosis in the International Classification of Diseases, 11th Revision (ICD-11) since 2022. Catatonia is found in 5-18% of inpatients on psychiatric units and 3.3% of inpatients on medical units. However, in an unknown number of patients, catatonia remains unrecognized and these patients are at risk of life-threatening complications. Hence, recognizing the symptoms of catatonia early is crucial to initiate appropriate treatment to achieve a favourable outcome. Benzodiazepines such as lorazepam and diazepam, electroconvulsive therapy, and N-methyl-D-aspartate antagonists such as amantadine and memantine, are the cornerstones of catatonia therapy. In addition, dopamine-modulating second-generation antipsychotics (for example, clozapine and aripiprazole) are effective in some patient populations. Early and appropriate treatment combined with new screening assessments has the potential to reduce the high morbidity and mortality associated with catatonia in psychiatric and non-psychiatric settings.
Asunto(s)
Benzodiazepinas , Catatonia , Terapia Electroconvulsiva , Catatonia/diagnóstico , Catatonia/terapia , Catatonia/fisiopatología , Catatonia/etiología , Humanos , Terapia Electroconvulsiva/métodos , Benzodiazepinas/uso terapéutico , Lorazepam/uso terapéutico , Antipsicóticos/uso terapéutico , Amantadina/uso terapéutico , Memantina/uso terapéutico , Diazepam/uso terapéuticoRESUMEN
ABSTRACT: This is the first report of pediatric catatonia syndrome in MED13L haploinsufficiency syndrome. This report describes unique challenges in diagnosis and management of catatonia in rare genetic conditions. The case also illustrates the use of electroconvulsive therapy in patients with epilepsy, epileptic encephalopathy, or other epileptic diathesis and the clinical conundrum in determining the course of maintenance electroconvulsive therapy.
Asunto(s)
Catatonia , Terapia Electroconvulsiva , Epilepsia , Haploinsuficiencia , Humanos , Catatonia/terapia , Catatonia/genética , Catatonia/complicaciones , Adolescente , Epilepsia/genética , Epilepsia/complicaciones , Epilepsia/terapia , Complejo Mediador/genética , Masculino , FemeninoRESUMEN
OBJECTIVE: Catatonia is a neuropsychiatric disorder associated with changes in behavior and affect. In adults, catatonia can respond rapidly to treatment with benzodiazepines as part of the "lorazepam challenge test." The acute effectiveness of benzodiazepine treatment in pediatric catatonia, however, has received less study. This study reports catatonia severity as measured by the Bush Francis Catatonia Rating Scale (BFCRS) in pediatric patients before and after treatment with lorazepam. METHODS: Multicenter retrospective cohort study from 1/1/2018 to 6/1/2023 of patients aged 18 and younger with a clinical diagnosis of catatonia and assessment using the BFCRS before and after treatment with lorazepam. RESULTS: Among 54 patients, median age was 16, and 26 (48.1 %) were female. Neurodevelopmental disabilities were present in 24 (44.4 %) of patients. Prior to treatment, patients had a mean BFCRS score of 16.6 ± 6.1, which significantly reduced to 9.5 ± 5.3 following treatment with lorazepam (mean paired difference 7.1; t = 9.0, df = 53, p < 0.001), representing a large effect size (Hedges's g = 1.20; 95 % CI: 0.85 to 1.55). No significant association was found between lorazepam dose or route of administration and clinical response, nor were age, sex, study site, the presence of a neurodevelopmental disorder, the presence of hyperactive catatonic features, or the time between treatment and reassessment associated with post-treatment BFCRS. CONCLUSIONS: Lorazepam resulted in a rapid improvement in BFCRS score in pediatric patients, with a large effect size. Further research is needed into optimal dosing and route of administration of the lorazepam challenge test in pediatric patients.
Asunto(s)
Catatonia , Lorazepam , Humanos , Lorazepam/administración & dosificación , Lorazepam/farmacología , Lorazepam/uso terapéutico , Femenino , Masculino , Catatonia/tratamiento farmacológico , Catatonia/diagnóstico , Estudios Retrospectivos , Adolescente , Niño , Preescolar , Resultado del Tratamiento , Índice de Severidad de la EnfermedadRESUMEN
Malignant catatonia (MC) is a complex, life-threatening condition characterized by motor dysregulation and autonomic instability, which requires prompt and effective treatment. There are some limitations to the current recommendations for treating MC, including barriers to receiving ECT, failure to respond to benzodiazepines, or benzodiazepine intolerance. To the authors' knowledge, there are 3 case reports in the literature describing the use of amantadine in the treatment of MC. We present the case of a 51-year-old female with a history of multiple medical and psychiatric conditions who was admitted to the hospital for altered mental status. During her admission, she developed symptoms that raised concern about MC, which was initially managed with lorazepam. However, due to concerns about severe respiratory compromise, lorazepam was discontinued, and the patient was started on liquid amantadine. She showed marked reduction in the symptoms of malignant catatonia, and the autonomic instability resolved after she was started on amantadine. The patient was eventually discharged home with outpatient follow-up scheduled. Our case report shows successful treatment of MC with liquid amantadine in a patient who was unable to tolerate escalating doses of benzodiazepines. The positive response to amantadine suggests that it may be a useful treatment option for MC. While further studies are needed, clinicians should consider the use of amantadine in the treatment of MC, especially in patients who are unable to tolerate benzodiazepines, who have failed to respond to treatment with benzodiazepines, or who are being treated in institutions where the availability of ECT is limited. Amantadine may be more readily accessible given its multiple formulations and wide availability.
Asunto(s)
Amantadina , Catatonia , Humanos , Amantadina/administración & dosificación , Amantadina/uso terapéutico , Femenino , Persona de Mediana Edad , Catatonia/tratamiento farmacológico , Catatonia/etiología , Dopaminérgicos/administración & dosificación , Lorazepam/administración & dosificación , Lorazepam/uso terapéuticoAsunto(s)
Catatonia , Terapia Electroconvulsiva , Humanos , Catatonia/etiología , Catatonia/complicaciones , FemeninoRESUMEN
BACKGROUND: Catatonia, as a transdiagnostic construct, manifests across various psychiatric and non-psychiatric conditions. Understanding how symptom variations impact the catatonia construct and differ across primary diagnoses (schizophrenia, bipolar disorder, unipolar depression, and neurological/metabolic/immunological condition) is essential to refine diagnostic and therapeutic approaches. This study aims to compare the symptom networks and centrality measures of these diagnoses. METHODS: We conducted a network analysis using Bush-Francis Catatonia Rating Scale (BFCRS) data from 118 patients, examining centrality measures and network comparisons across the four primary diagnostic groups. RESULTS: In the general catatonia network, the three most central symptoms identified were Excitement (1.462), Perseveration (1.456), and Impulsivity (1.332). While the overall structure of the catatonia networks did not show significant differences between diagnoses in terms of symptom connections and centrality, variations in centrality measures were observed among the different networks. CONCLUSIONS: The study reinforces the notion of catatonia as an independent syndrome relatively to psychiatric or non-psychiatric diagnoses. However, the variation in centrality of symptoms across different primary diagnoses provides critical insights that could aid clinicians in tailoring diagnostic and therapeutic strategies. Future research should further explore these relationships and develop more refined approaches to managing catatonia.
Asunto(s)
Catatonia , Catatonia/diagnóstico , Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Trastorno Bipolar/diagnóstico , Escalas de Valoración Psiquiátrica , Adulto Joven , Esquizofrenia/diagnóstico , Esquizofrenia/complicacionesRESUMEN
Symptoms of catatonia include silence, motionlessness, and postural retention. Although it is important to detect and treat catatonia early, before it becomes severe, postoperative cases have inherent risks that hinder diagnosis and treatment. A 60-year-old man with schizophrenia underwent endoscopic/thoracoscopic esophagectomy and was extubated in the operating room. In the intensive care unit (ICU), he had stiffness in the neck, ankles, and knees, catalepsy during passive knee flexion, mild disturbance of consciousness, mild creatine kinase elevation, and respiratory depression. Intravenous diazepam was administered for diagnosis, and the patient's rapid improvement indicated catatonia. He was intubated and started on lorazepam; tapering produced no recurrence of symptoms. The patient was extubated and transferred to the general ward on postoperative Day 2. Because this patient was extubated in the operating room and was managed postoperatively in the ICU with a full-time doctor, his symptoms were easily recognized and early diagnosis was possible. Thus, we were able to administer drug therapy quickly and adequately and perform forward management that accounted for postoperative risks, thereby achieving a favorable outcome.
Asunto(s)
Catatonia , Diagnóstico Precoz , Lorazepam , Humanos , Masculino , Persona de Mediana Edad , Catatonia/diagnóstico , Catatonia/tratamiento farmacológico , Lorazepam/administración & dosificación , Lorazepam/uso terapéutico , Esofagectomía , Resultado del Tratamiento , Diazepam/administración & dosificación , Esquizofrenia/diagnóstico , Esquizofrenia/tratamiento farmacológico , Complicaciones Posoperatorias/diagnósticoAsunto(s)
Catatonia , Parálisis Cerebral , Terapia Electroconvulsiva , Epilepsia , Humanos , Catatonia/terapia , Catatonia/etiología , Epilepsia/terapia , Epilepsia/complicaciones , Femenino , Parálisis Cerebral/complicaciones , Parálisis Cerebral/terapia , Vasculitis por Lupus del Sistema Nervioso Central/terapia , Vasculitis por Lupus del Sistema Nervioso Central/complicaciones , AdultoRESUMEN
Lithium may cause toxicity as it has a narrow therapeutic range. Lithium intoxication may manifest in the form of acute, acute on chronic and chronic intoxication. Neurotoxicity is a common component of chronic lithium intoxication and the symptoms include tremor, ataxia, dysarthria, extrapyramidal symptoms, hyperreflexia, seizures and status epilepticus. Although rare, catatonia could as a manifestation of lithium neurotoxicity. In this report, we present a patient with bipolar disorder presenting with catatonic symptoms secondary to lithium intoxication. We will discuss the risk factors, differential diagnosis and the treatment of catatonic symptoms. Lithium neurotoxicity may present with various clinical symptoms including catatonia, and differential diagnosis should be made well in such cases. If lithium neurotoxicity is suspected, rapid and appropriate intervention is required to prevent permanent neurological damage. Keywords: Lithium, Neurotoxicity, Catatonia.
Asunto(s)
Trastorno Bipolar , Catatonia , Humanos , Antimaníacos/efectos adversos , Trastorno Bipolar/tratamiento farmacológico , Catatonia/inducido químicamente , Diagnóstico Diferencial , Síndromes de Neurotoxicidad/etiología , Síndromes de Neurotoxicidad/diagnósticoRESUMEN
Presented clinical observation of anti-NMDA-receptor encephalitis, which was first described in 2007, is rare and to date has not been sufficiently studied. The disease often manifests with psychopathological symptoms and catatonia, so patients are transferred into a mental healthcare institution and often require intensive care and resuscitation, due to the development of life-threatening respiratory and hemodynamic disorders. Diagnosis is based on detection of autoantibodies to the NR1- and NR2 subunits of the glutamate NMDA receptor in blood serum and cerebrospinal fluid. Pathogenesis-based therapy includes the administration of glucocorticoids and intravenous immunoglobulins, plasmapheresis, as well as the introduction of monoclonal antibodies in also used, and in severe cases, cytostatics are prescribed. The widespread comorbidity of anti-NMDA receptor encephalitis with ovarian neoplasms in women (up to 60%) requires appropriate diagnosis and early removal of ovarian neoplasms when they are detected. With timely diagnosis and adequate treatment strategies, the outcome of this rare disorder is usually positive.
Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato , Autoanticuerpos , Neoplasias Ováricas , Adulto , Femenino , Humanos , Encefalitis Antirreceptor N-Metil-D-Aspartato/diagnóstico , Encefalitis Antirreceptor N-Metil-D-Aspartato/complicaciones , Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Catatonia/etiología , Catatonia/diagnóstico , Inmunoglobulinas Intravenosas/uso terapéutico , Trastornos Mentales/etiología , Trastornos Mentales/diagnóstico , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/diagnóstico , Plasmaféresis , Receptores de N-Metil-D-Aspartato/metabolismoRESUMEN
ABSTRACT: The SCN2A gene encodes a subunit that forms part of voltage-gated sodium channels in the brain. Gain-of-function mutations are associated with epilepsy as well as numerous movement/motor abnormalities. Loss-of-function mutations may also cause epilepsy in addition to a variety of neurodevelopmental anomalies, including autism and intellectual disability. The occurrence of catatonia has also been described in 1 previous report that involved a 4-year-old boy. We describe a 20-year-old intellectually disabled female patient who developed recurrent catatonic symptoms in her teenage years that remitted with electroconvulsive therapy. This is only the second report of catatonia occurring in relation to an SCN2A mutation and the first involving a female. Moreover, this case is unique given our patient's later age of symptom onset and given that her symptoms responded well to electroconvulsive therapy.
Asunto(s)
Catatonia , Terapia Electroconvulsiva , Canal de Sodio Activado por Voltaje NAV1.2 , Humanos , Catatonia/terapia , Catatonia/genética , Femenino , Canal de Sodio Activado por Voltaje NAV1.2/genética , Adulto Joven , Discapacidad Intelectual/genética , Discapacidad Intelectual/terapia , MutaciónRESUMEN
Catatonia is a complex syndrome with unique cognitive, psychomotor, and mood features. Mannerisms and stereotypies are catatonic signs that have been extensively observed and described in the literature, mostly in the context of movements or motor acts. Stereotypies are commonly described as repetitive psychomotor or verbal acts with the abnormality not inherent in the act but in its frequency. Mannerisms, like stereotypies, are repetitive psychomotor or verbal acts, but they are fundamentally odd in nature. Recently, several reports have described these phenomena in the context of complex behaviors, such as eating and drinking. Identification and appreciation of personal and cultural norms, in addition to a careful analysis of behavioral processes and actions, are important tools for clinicians to identify these potentially elusive and often missed patterns of behavior in patients with catatonia. We present the case of a 30-year-old male with a psychiatric history of treatment-resistant, recurrent major depressive disorder with psychotic features who presented to the inpatient psychiatric unit with signs of catatonia, including repeated, purposeless eating. The patient's chart was reviewed, and a literature review was conducted using PubMed with the keywords catatonia, stereotypies, mannerisms, and hyperphagia. The patient, who was diagnosed with catatonia and expressed hyperphagia as a stereotypy, responded to lorazepam. This case shows that hyperphagia may present as a stereotypy in patients with catatonia.
Asunto(s)
Catatonia , Hiperfagia , Humanos , Catatonia/etiología , Catatonia/tratamiento farmacológico , Masculino , Hiperfagia/psicología , Hiperfagia/etiología , Adulto , Conducta Estereotipada , Trastorno Depresivo Mayor , Lorazepam/uso terapéutico , Lorazepam/administración & dosificaciónRESUMEN
Electroconvulsive therapy (ECT) is an effective and safe treatment method for many psychiatric disorders. In general medical practice, ECT may cause side effects as most other treatment methods do. Headache, myalgia, nausea, vomiting, confusion, anterograde amnesia are common side effects of electroconvulsive therapy. Fever; in addition to general medical conditions such as infection, malignancy, connective tissue diseases, drug treatments, malignant hyperthermia, convulsions, it can also occur due to conditions such as neuroleptic malignant syndrome (NMS), serotonin syndrome, catatonia, malignant catatonia, which are frequently encountered in psychiatry clinics. In the literature, transient fever response due to electroconvulsive therapy application have been described, albeit rarely. Although there are many proposed mechanisms for the emergence of a fever response, regardless of its cause, it is still not understood why some fever responses occur. In this article, we present the differential diagnosis of the fever response, possible causes, and the mechanisms that may reveal the secondary fever response to electroconvulsive therapy in a case with a diagnosis of catatonic schizophrenia, who developed a fever response during electroconvulsive therapy sessions and no fever response was observed at times other than electroconvulsive therapy sessions. In this case, postictal benign fever response associated with electroconvulsive therapy was considered after excluding other medical conditions that may cause a fever response after electroconvulsive therapy. Keywords: ECT, Fever, Catatonia, NMS.
Asunto(s)
Catatonia , Terapia Electroconvulsiva , Síndrome Neuroléptico Maligno , Esquizofrenia , Humanos , Esquizofrenia Catatónica/complicaciones , Esquizofrenia Catatónica/terapia , Catatonia/etiología , Catatonia/terapia , Catatonia/diagnóstico , Esquizofrenia/complicaciones , Esquizofrenia/terapia , Terapia Electroconvulsiva/efectos adversos , Terapia Electroconvulsiva/métodos , Síndrome Neuroléptico Maligno/complicaciones , Síndrome Neuroléptico Maligno/diagnósticoRESUMEN
BACKGROUD: Catatonia encompasses a group of severe psychomotor syndromes affecting patients' motor, speech, and complex behaviors. Common features include rigidity, reduced mobility, speech, sputum production, defecation, and eating. Risks associated with catatonia, such as increased muscle tension and reduced swallowing and coughing reflexes, along with risks from therapeutic approaches like prolonged bed rest and sedative drugs, can elevate the risk of aspiration pneumonia, severe pneumonia, and acute respiratory failure. These complications significantly impede catatonia treatment, leading to poor prognosis and jeopardizing patient safety. CASE DESCRIPTION: In this report, we present a case of catatonia complicated by severe pneumonia and respiratory failure, successfully managed with modified electroconvulsive therapy alongside tracheotomy. We hope this case provides valuable insights for psychiatrists encountering similar scenarios, facilitating the development of rational therapeutic strategies for prompt improvement of patient condition.
Asunto(s)
Catatonia , Terapia Electroconvulsiva , Neumonía , Insuficiencia Respiratoria , Humanos , Traqueotomía/efectos adversos , Catatonia/terapia , Catatonia/tratamiento farmacológico , Neumonía/complicaciones , Insuficiencia Respiratoria/complicaciones , Insuficiencia Respiratoria/terapiaRESUMEN
RATIONALE: Turner syndrome (TS) is a genetic disorder associated with partial or complete monosomy X abnormalities; some patients may have a higher risk of psychiatric symptoms. Catatonia is associated with a wide range of life-threatening complications with complex pathogenesis; However, It very rare for patients with TS to develop psychotic symptoms and eventually progress to catatonia. This case report describes the diagnostic and therapeutic course of catatonia-associated TS. PATIENT CONCERNS: In this study, we report the case of a patient with TS who initially developed sudden hallucinations, delusions, and emotional instability, followed by catatonia. DIAGNOSES: The patient was diagnosed with: unspecified catatonia; TS. INTERVENTIONS: Treatment included administering a combination of esazolam injections and olanzapine tablets, placing a gastric tube and urinary catheter, and providing nutritional support. OUTCOMES: After treatment, the patient's hallucinations, delusions, and catatonia disappeared, with no residual sequelae, and social functioning returned to normal. LESSONS: For patients with TS who present with psychotic symptoms and catatonia, a comprehensive evaluation is necessary, and treatment with antipsychotics and benzodiazepines is effective.